combining venetoclax and obinutuzumab in the treatment of cll
Published 7 years ago • 793 plays • Length 3:22Download video MP4
Download video MP3
Similar videos
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:07
preliminary promise for venetoclax and 3 7 in untreated aml
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
1:52
novel options for patients with cll who relapse after treatment with btk inhibitors and venetoclax
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
1:22
promising outlooks for venetoclax combinations for mm
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
54:22
the recording of the webinar invocation of the consensus
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
2:05
a phase ii study investigating epcoritamab in the treatment of waldenström’s macroglobulinemia
-
2:46
optimizing the combination of ibrutinib plus venetoclax in cll
-
1:25
the potential of triplet regimens combining btkis with venetoclax and obinutuzumab in cll
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
1:34
captivate study: outcomes in patients with umrd following cessation of ibrutinib plus venetoclax
-
0:50
management of variant acute promyelocytic leukemia
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
2:29
the role of the multidisciplinary team in providing adequate diagnosis & treatment for bpdcn
-
2:44
the global expansion of modern aml therapy through the international consortium on acute leukemia
-
2:09
overview of the cll13 trial: replacing chemotherapy with venetoclax-containing regimens
-
3:36
the long-term outcomes of consolidative allosct for bpdcn